Register for our free email digests:
People
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Sandoz Head Francis To Leave Amid Move Towards Autonomy
People Roundup – 7 March 2019
Biocon believes its new biologics chief in India will lead the firm to become a “major global player”, Glenmark names Riva to lead its recently spun-off innovation business, and Recipharm bolsters its management team by adding Chouhan to lead sales activity in North America.
Acino Adds Four To Senior Management Team
Acino has bolstered its senior management team with four appointments, as the Swiss firm aims to strengthen its position as a high-quality pharmaceutical company focusing on emerging markets.
Kox Named As IGBA Secretary General
Industry veteran Suzette Kox has been nominated as secretary general of the International Generic and Biosimilar medicines Association.
Neuraxpharm Strengthens French Business By Appointing Brun As General Manager
European CNS specialist Neuraxpharm is set to enhance its position in the French market by appointing Pierre-Hervé Brun as general manager of its French affiliate. The firm has also strengthened its international identity by rebranding its Spanish subsidiary Qualigen to Neuraxpharm Spain.
Dr Reddy's Brings In Kikuchi To Lead North America Generics
Dr Reddy’s has added to its senior leadership team by appointing Marc Kikuchi as CEO of North America Generics. With a record number of US launches in Q3, potentially more in store and now a new leader to steer things through, the firm has improved its outlook for a significant revival in earnings. But risks of delays and competition on certain key anticipated launches in 2019 could dull prospects.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.